{"id":{"repo_id":"wfu","oai_identifier":"oai:wakespace.lib.wfu.edu:10339/57145"},"canonical_url":"https://search.dev.ndltd.org/etd/wfu/oai:wakespace.lib.wfu.edu:10339/57145","repository":{"repo_id":"wfu","name":"Wake Forest University","base_url":"https://wakespace.lib.wfu.edu/oai/request"},"display":{"title":"THE NOVEL GEMCITABINE PHOSPHOLIPID CONJUGATE KPC34 HAS ACTIVITY AGAINST MULTIPLE MODELS OF RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA","abstract":"Acute leukemias are cancers of the blood and bone marrow that affect thousands of Americans annually. These diseases can be myeloid or lymphoid in origin. Common components of therapy for both types of disease involve cytarabine and an anthracycline. After initially responding to treatment, most patients eventually relapse with disease that is resistant to conventional modalities. There is a pressing need for novel therapeutic agents to treat the acute leukemias, especially in the relapsed setting.","abstract_html":"Acute leukemias are cancers of the blood and bone marrow that affect thousands of Americans annually. These diseases can be myeloid or lymphoid in origin. Common components of therapy for both types of disease involve cytarabine and an anthracycline. After initially responding to treatment, most patients eventually relapse with disease that is resistant to conventional modalities. There is a pressing need for novel therapeutic agents to treat the acute leukemias, especially in the relapsed setting.","abstract_has_math":false,"creators":["Alexander, Peter M."],"institution":"Wake Forest University","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015","date_published":"2015","updated_at":"2026-07-27T22:01:52Z","subjects":["Chemoresistance"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10339/57145","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Alexander, Peter M."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2015-06-23T08:35:52Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2017-06-22T08:30:09Z"]},{"key":"dc:date.issued","label":"Date","values":["2015"]},{"key":"dc:publisher","label":"Institution","values":["Wake Forest University"]},{"key":"dc:type","label":"Dc Type","values":["Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chemoresistance"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10339/57145"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Acute leukemias are cancers of the blood and bone marrow that affect thousands of Americans annually. These diseases can be myeloid or lymphoid in origin. Common components of therapy for both types of disease involve cytarabine and an anthracycline. After initially responding to treatment, most patients eventually relapse with disease that is resistant to conventional modalities. There is a pressing need for novel therapeutic agents to treat the acute leukemias, especially in the relapsed setting."]},{"key":"dc:title","label":"Title","values":["THE NOVEL GEMCITABINE PHOSPHOLIPID CONJUGATE KPC34 HAS ACTIVITY AGAINST MULTIPLE MODELS OF RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA"]}]}],"canonical_facts":{"dc:creator":["Alexander, Peter M."],"dc:date.accessioned":["2015-06-23T08:35:52Z"],"dc:date.available":["2017-06-22T08:30:09Z"],"dc:date.issued":["2015"],"dc:description.abstract":["Acute leukemias are cancers of the blood and bone marrow that affect thousands of Americans annually. These diseases can be myeloid or lymphoid in origin. Common components of therapy for both types of disease involve cytarabine and an anthracycline. After initially responding to treatment, most patients eventually relapse with disease that is resistant to conventional modalities. There is a pressing need for novel therapeutic agents to treat the acute leukemias, especially in the relapsed setting."],"dc:identifier.uri":["http://hdl.handle.net/10339/57145"],"dc:language.iso":["en"],"dc:publisher":["Wake Forest University"],"dc:subject":["Chemoresistance"],"dc:title":["THE NOVEL GEMCITABINE PHOSPHOLIPID CONJUGATE KPC34 HAS ACTIVITY AGAINST MULTIPLE MODELS OF RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA"],"dc:type":["Dissertation"]},"updated_at":"2026-07-27T22:01:52Z"}